Clinical Trial

A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This multi-center, prospective, longitudinal cohort study is designed to gather immunological and clinical data on EBV reactivation in EBV seropositive adults aged 18 to 29 years. This study will follow a cohort of approximately 100 EBV seropositive adults 18 to 29 years of age in Australia over a 6 or 12-month period. Participants will not receive any study intervention (eg, study treatments, vaccines).
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-20
critical Recruitment opened 2026-05-12
Trial Details
NCT Number NCT07536048
Lead Sponsor Sanofi Pasteur, a Sanofi Company
Conditions Epstein-Barr Virus (EBV), Healthy Volunteers
Enrollment 100 participants
Start Date 2026-04-20
Primary Completion 2027-05-14 (estimated)
Study Completion 2027-05-14 (estimated)
Updated on ClinicalTrials.gov 2026-06-11